SECTION 1. Section 47T of Chapter 175 of the General Laws is hereby amended by adding the following additional new section:
Section 47U: The commissioner shall establish an advisory panel of five medical experts to advise the commissioner on whether off-label uses for rheumatologic disease treatment not included in any of the standard reference compendia or in the medical literature are medically appropriate. The panel shall advise the commissioner whenever a dispute about coverage of such off-label prescription drugs prescribed by a physician is brought to the commissioner. All members of the advisory panel shall have significant expertise in treating rheumatologic disease, and the panel shall include at least one physician representing commercial insurers.
After consulting with said advisory panel, the commissioner may direct an insurer to make payments required by section forty-seven O of chapter one hundred and seventy-five, section eight P of chapter one hundred and seventy-six A, section four O of chapter one hundred and seventy-six B, and section four F of chapter one hundred and seventy-six G.
SECTION 2. Section 47K of Chapter 175 of the General Laws is hereby amended by adding after the phrase “treatment of cancer” in the first, fourth, and eighth paragraphs the words “or rheumatologic disease”.
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.